Agoracom

AlphaRx International Holdings Limited ("AIH"), subsidiary of AlphaRx Inc. (OTCBB: ALRX), announces that they are entering into the multi billion dollars oncology market with two nanotechnology based products, to address hepatic and lung cancer respectively. The Company's first lead product is a biodegradable nanoparticle based injectable formulation of Doxorubicin targeted to treat primary liver cancer (hepatocellular carcinoma - HCC). Doxorubicin is one of the most widely prescribed therapeutic agents in the treatment of cancer. As a single agent or in combination therapy, doxorubicin has a 15-20% response rate in HCC, making it one of the more effective drugs available. However, a high risk of cardiac toxicity is associated with doxorubicin and this limits its use as a first line treatment for non-resectable patients. The Company believes that its' Doxorubicin nanoparticle formulation may overcome resistance by bypassing Multi Drug Resistance (MDR) mechanisms and thereby reducing its cardiac side effects. (MDR's are cancer cell adaptations which activate transmembrane transporter proteins, actively pumping the therapeutic agents outside the cancer cell shortly after their cellular absorption, limiting their effectiveness. It is this efflux of drug extracellularly or intracellular redistribution of the agent which leads to cardiac toxicity.) The Company's second lead product is a biodegradable nanoparticle based inhalable formulation of Paclitaxel, targeted to treat non-small cell lung cancer (NSCLC). NSCLC accounts for nearly 80% of all lung cancers, with 1.2 million new cases diagnosed worldwide each year. The 5-year survival rate for these patients is approximately 15%, and lung cancer remains the leading cause of cancer-related mortality in the western world. The Company's Paclitaxel formulation is administered directly to the lung by inhalation vs. the traditional systemic I.V. administration method. Such localized administration is expected to be more effective, more convenient to administer and possessing fewer side effects. About AlphaRx International Holdings Limited (AIH) AIH based in Hong Kong, is a subsidiary of AlphaRx Inc. (OTCBB: ALRX). AIH's mission is to become a leading developer, manufacturer and marketer of innovative pharmaceutical products in Asia through its strategic and joint venture partners. Currently, AIH is focusing on developing nanotechnology based drugs for the oncology market, the Company's lead products is a nanoparticle based formulation of Doxorubicin and Paclitaxel intended to treat hepatic cancer and non-small cell lung cancer respectively.